We are live on ! Find out more
RSCM

Rock Springs Capital Management Portfolio holdings

AUM $1.7B
1-Year Est. Return 93.03%
This Fund
S&P 500
This Quarter Est. Return
+8.8%
1 Year Est. Return
+93.03%
3 Year Est. Return
+228.43%
5 Year Est. Return
+368.14%
10 Year Est. Return
+4,607.77%
AUM
$5.06B
AUM Growth
+$476M
Cap. Flow
+$367M
Cap. Flow %
7.25%
Top 10 Hldgs %
27.38%
Holding
165
New
14
Increased
67
Reduced
10
Closed
9

Top Buys

Rank Stock Value
1
AGL icon
Agilon Health
AGL
+$245M
2
LENZ
LENZ Therapeutics
LENZ
+$53.5M
3
NEUE
NeueHealth
NEUE
+$40.7M
4
VERV
Verve Therapeutics
VERV
+$40M
5
LFST icon
Lifestance Health
LFST
+$39.6M

Top Sells

Rank Stock Value
1
FPRX
Five Prime Therapeutics, Inc.
FPRX
+$100M
2
AZN icon
AstraZeneca
AZN
+$32.3M
3
AVIR icon
Atea Pharmaceuticals
AVIR
+$27.2M
4
INSP icon
Inspire Medical Systems
INSP
+$20.7M
5
UNH icon
UnitedHealth
UNH
+$14M

Sector Composition

Rank Sector Weight
1 Healthcare 94.21%
2 Consumer Staples 1.63%
3 Industrials 0.71%
4 Financials 0.1%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
SRRA
76
DELISTED
Sierra Oncology, Inc. Common Stock
SRRA
$19.8M 0.39%
1,018,658
+1,300
+0.1% +$23.6K
DXCM icon
77
DexCom
DXCM
$32B
$19.5M 0.38%
182,400
+122,400
+204% +$11.8M
INNV icon
78
InnovAge Holding
INNV
$1.52B
$19.2M 0.38%
902,500
+427,500
+90% +$9.78M
TBIO
79
DELISTED
Translate Bio, Inc. Common Stock
TBIO
$19.1M 0.38%
693,266
+43,366
+7% +$852K
AMRN
80
Amarin Corp
AMRN
$303M
$18.9M 0.37%
216,000
+6,250
+3% +$614K
BMEA icon
81
Biomea Fusion
BMEA
$91.3M
$18.2M 0.36%
+1,165,582
New +$20.6M
SPRB
82
Spruce Biosciences
SPRB
$129M
$18M 0.36%
21,400
+343
+2% +$366K
RCKT icon
83
Rocket Pharmaceuticals
RCKT
$394M
$17.9M 0.35%
403,270
+200
+0% +$8.69K
KURA icon
84
Kura Oncology
KURA
$850M
$17M 0.34%
816,800
+106,765
+15% +$2.65M
AVIR icon
85
Atea Pharmaceuticals
AVIR
$420M
$17M 0.34%
791,133
-903,770
-53% -$27.2M
DVAX
86
DELISTED
Dynavax Technologies
DVAX
$16.5M 0.33%
1,679,921
+21,401
+1% +$195K
RLAY icon
87
Relay Therapeutics
RLAY
$4.33B
$16.5M 0.33%
450,258
+198,131
+79% +$6.53M
NKTX icon
88
Nkarta
NKTX
$172M
$15.8M 0.31%
497,948
+6,100
+1% +$176K
CHMA
89
DELISTED
Chiasma, Inc. Common Stock
CHMA
$15.4M 0.3%
3,258,144
+1,083,561
+50% +$4.08M
RXDX
90
DELISTED
Prometheus Biosciences, Inc. Common Stock
RXDX
$14.6M 0.29%
596,096
+21,238
+4% +$474K
OLK
91
DELISTED
Olink Holding AB (publ) American Depositary Shares
OLK
$14.6M 0.29%
425,000
+25,000
+6% +$858K
APLT
92
DELISTED
Applied Therapeutics
APLT
$14.6M 0.29%
701,680
– –
MREO
93
Mereo BioPharma
MREO
$47.3M
$14.4M 0.28%
4,542,769
+47,900
+1% +$161K
EPIX
94
DELISTED
ESSA Pharma
EPIX
$14.4M 0.28%
503,035
– –
INZY
95
DELISTED
Inozyme Pharma
INZY
$14.3M 0.28%
840,272
+12,372
+1% +$215K
ANAB icon
96
AnaptysBio
ANAB
$1.68B
$13.9M 0.27%
535,232
– –
GMDA
97
DELISTED
Gamida Cell Ltd. Ordinary Shares
GMDA
$13.5M 0.27%
2,107,000
+6,700
+0.3% +$46.2K
SPRO icon
98
Spero Therapeutics
SPRO
$73M
$13.5M 0.27%
965,928
– –
AKRO
99
DELISTED
Akero Therapeutics
AKRO
$13.1M 0.26%
528,601
+7,430
+1% +$209K
LEGN icon
100
Legend Biotech
LEGN
$4.01B
$12.8M 0.25%
312,618
– –
2 3
4
5 6

Similar funds

ACM
ADAR1 Capital Management Austin, Texas $1.7B AUM 340.85% 1-Year Est. Return
BCM
BlueCrest Capital Management St Helier, Jersey $1.69B AUM 20.01% 1-Year Est. Return
PP
PDT Partners New York $1.69B AUM 74.01% 1-Year Est. Return
GAM
Goldentree Asset Management New York $1.69B AUM 10.69% 1-Year Est. Return
FACM
Forest Avenue Capital Management Miami, Florida $1.69B AUM 104.84% 1-Year Est. Return
RMC
Ribbit Management Company Palo Alto, California $1.68B AUM 40.61% 1-Year Est. Return
JIP
Jaffetilchin Investment Partners Tampa, Florida $1.68B AUM 22.81% 1-Year Est. Return
II
Inspire Investing Meridian, Idaho $1.71B AUM 31.76% 1-Year Est. Return

Rock Springs Capital Management's Q2 2021 Portfolio in Review

As of Q2 2021, Rock Springs Capital Management held 165 positions worth $5.06B, up 10% from $4.58B the previous quarter. Its ten largest holdings account for 27% of the portfolio.

Rock Springs Capital Management deployed $367M of net new capital in Q2 2021, opening 14 new positions and adding to 67 existing holdings. Its largest new stake was Agilon Health: 279,961 shares worth $284M.

By sector, the portfolio is most concentrated in Healthcare at 94% of assets, up from 94% a quarter earlier, followed by Consumer Staples and Industrials.

On the sell side, the largest reduction was Atea Pharmaceuticals, an estimated $27.2M trimmed.

  • Rock Springs Capital Management's largest Q2 2021 buy was Agilon Health: 279,961 shares worth $284M.
  • Rock Springs Capital Management added most to Eargo, Inc. Common Stock in Q2 2021, an estimated $25.1M increase.
  • Rock Springs Capital Management's biggest Q2 2021 reduction was Atea Pharmaceuticals, cutting an estimated $27.2M.
  • Rock Springs Capital Management fully exited Five Prime Therapeutics, Inc. in Q2 2021, selling an estimated $100M.
  • Rock Springs Capital Management's ten largest holdings make up 27% of its $5.06B portfolio in Q2 2021.
  • Rock Springs Capital Management opened 14 new positions and closed 9 in Q2 2021.
  • Rock Springs Capital Management's portfolio value rose 10% quarter-over-quarter to $5.06B.

Based on Rock Springs Capital Management's 13F filing for Q2 2021, filed 16 Aug 2021.